Hugel to Participate in 'IMCAS 2025'... Showcasing Excellence of HA Fillers and Suture Products

Hugel Subsidiaries Across and JWorld Operate Booths

On-site booth showcasing Hugel products such as HA fillers and sutures. Photo by Hugel

Global total medical aesthetic specialist company Hugel Co., Ltd. is participating in the 'IMCAS World Congress 2025' for the fourth consecutive year. They operated a dedicated booth introducing HA (hyaluronic acid) fillers and suture products. In addition, Hugel's CEO Moon Hyeong-jin participated as a roundtable panelist on the topic of 'Botulinum Toxin,' discussing the direction of market development.

IMCAS (International Master Course on Aging Science) is the world's largest global aesthetic surgery conference. This event was held in Paris, France, from January 30 to February 1, with about 18,000 industry professionals from dermatology, plastic surgery, and related fields attending.

Hugel's subsidiaries, HA filler company 'Across' and suture manufacturing company 'JWorld,' set up dedicated booths at IMCAS to showcase the differentiated product capabilities and excellence of Hugel's various products to global medical professionals.

The HA filler 'Revolax' (domestic product name The Chaeum) is currently available in 48 countries worldwide and is sold in 25 European countries alone. Centered on the European Big 5 countries?United Kingdom, France, Germany, Italy, and Spain?it is strengthening its position and plans to continue stable growth in the global market this year.

The absorbable suture 'Licellvi' (domestic product name Blue Rose Forte) is also accelerating its global expansion. After first obtaining approval in Thailand in 2023, it has completed product approvals in a total of 18 countries including Europe, Brazil, Bulgaria, and Vietnam.

A Hugel representative said, "We are pleased to participate in IMCAS, the largest academic event in the medical aesthetic field, for the fourth consecutive year and to showcase the excellence of Hugel's products. We will continue to actively communicate with medical professionals and industry stakeholders worldwide to promote our corporate value and product capabilities."